Restless Legs Syndrome: A Comprehensive Review of Current Treatment Methods and the Disease's Impact on Quality of Life

• Published in: Quality in Sport 2025-01, Vol.37, p.57723
• Main Authors: Papachristoforou, Natalie, Tekiela, Natalia, Michałka, Daria, Gałuszka, Zuzanna, Makar, Monika, Bartuś, Tomasz, Bąk, Emilia, Głowacka, Justyna, Kocjan, Aleksandra, Chmiel, Radosław
• Format: Article
• Language: English
• Subjects: neurotransmitter dysfunction; Restless leg syndrome; sensorimotor disorder; Willis-Ekbom disease
• ISSN: 2450-3118; 2450-3118
• DOI: 10.12775/QS.2024.37.57723

Introduction and Purpose of Research: Restless Leg Syndrome (RLS) or Willis-Ekbom disease, is a common neurological disorder significantly impacting one’s sleep and quality of life. It often coexists with various health issues, including diabetes and cardiovascular diseases. Aim of study: The primary purpose of this research is to explore diverse therapeutic options for RLS which are tailored to individual patient needs. In order to understand the complex pathophysiology of the discussed disease, recent advancements are taken into account. Material and Methods of Research:  The review is grounded in findings from 36 recent studies sourced through a systematic search of open-access databases, including PubMed and Google Scholar, focusing on literature published between 2004 and 2024. Results: Adequate and effective management of RLS include non-pharmacological interventions, such as physical activity, acupuncture, yoga and near-infrared light therapy, which can complement pharmacotherapy or prevail as the primary treatment form. Iron therapy emerges as vital for many patients. The correlation between iron metabolism and RLS symptoms requires further analysis and research. Pharmacological strategies involve dopaminergic medications, low-potency opioids, and benzodiazepines, with a target on minimizing side effects and dependency. Conclusion: RLS affects approximately 5-10% of the population, severely disrupting sleep and daily functioning. The condition constrains individualized management, integrating non-pharmacological forms of treatment with pharmacological therapies to improve patient outcomes and reduce dependence on medication.